Patients in Australia presently have a option of getting Nivolumab or Pembrolizumab for advanced melanoma. Neither of the medications are presently funded on the Pharmaceutical Benefits Scheme (Pembro will be from 1st Sep 2015), but are available via Access programmes from the companies. Great drugs. Great benefits. Significantly lowered toxicity profile.
Worth having a discussion with your Oncology doctor.